- Home
- DOUG vs SKYE Comparison
DOUG vs SKYE Comparison
Compare DOUG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- SKYE
- Stock Information
- Founded
- DOUG 1911
- SKYE 2012
- Country
- DOUG United States
- SKYE United States
- Employees
- DOUG N/A
- SKYE N/A
- Industry
- DOUG Building operators
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- SKYE Health Care
- Exchange
- DOUG Nasdaq
- SKYE Nasdaq
- Market Cap
- DOUG 161.5M
- SKYE 115.9M
- IPO Year
- DOUG N/A
- SKYE N/A
- Fundamental
- Price
- DOUG $2.49
- SKYE $3.98
- Analyst Decision
- DOUG
- SKYE Buy
- Analyst Count
- DOUG 0
- SKYE 6
- Target Price
- DOUG N/A
- SKYE $16.60
- AVG Volume (30 Days)
- DOUG 1.0M
- SKYE 2.2M
- Earning Date
- DOUG 08-06-2025
- SKYE 08-08-2025
- Dividend Yield
- DOUG N/A
- SKYE N/A
- EPS Growth
- DOUG N/A
- SKYE N/A
- EPS
- DOUG N/A
- SKYE N/A
- Revenue
- DOUG $1,048,791,000.00
- SKYE N/A
- Revenue This Year
- DOUG $17.61
- SKYE N/A
- Revenue Next Year
- DOUG N/A
- SKYE N/A
- P/E Ratio
- DOUG N/A
- SKYE N/A
- Revenue Growth
- DOUG 11.36
- SKYE N/A
- 52 Week Low
- DOUG $1.17
- SKYE $1.14
- 52 Week High
- DOUG $3.20
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- DOUG 51.83
- SKYE 60.88
- Support Level
- DOUG $2.27
- SKYE $3.65
- Resistance Level
- DOUG $2.61
- SKYE $4.75
- Average True Range (ATR)
- DOUG 0.12
- SKYE 0.71
- MACD
- DOUG -0.01
- SKYE 0.00
- Stochastic Oscillator
- DOUG 56.58
- SKYE 48.55
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.